Internal Medicine, Hematology & Oncology · Las Vegas, NV
NPI
1336263953
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
2650 N Tenaya Way Ste 201
Las Vegas, NV, 89128
Phone (702) 735-7154
Groups this clinician bills Medicare through
Medicare paid, 2024
$331K
26,529 services
Medicare patients, 2024
65
Average age 75
Drug cost, 2024
$4.6M
1,425 prescriptions
Company payments, 2024
$14.76
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Randy R Calegari was code 99214 (office e&m - established), 169 times for 59 patients. In total Randy R Calegari billed 26,529 services in 72 codes, and Medicare paid $331K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-06-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 169 | 59 | $92.78 | $16K |
| 85025 Blood Count | Office | 167 | 38 | $7.61 | $1,271 |
| 36415 Venipuncture Blood Collection | Office | 142 | 32 | $8.65 | $1,228 |
| 96365 Intravenous Infusion, Hydration | Office | 52 | 13 | $46.87 | $2,437 |
| 80053 Clinical Chemistry | Office | 43 | 19 | $10.35 | $445 |
| 83615 Clinical Chemistry | Office | 38 | 18 | $5.92 | $225 |
| 83540 Clinical Chemistry | Office | 27 | 16 | $6.34 | $171 |
| 82728 Clinical Chemistry | Office | 27 | 16 | $13.36 | $361 |
| 84466 Clinical Chemistry | Office | 26 | 16 | $12.50 | $325 |
| 82607 Clinical Chemistry | Office | 21 | 15 | $14.78 | $310 |
By year: 2023 $207K for 14,213 services; 2024 $331K for 26,529 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 167 | 38 | $7.61 | $1,271 |
| 36415 Venipuncture Blood Collection | 142 | 32 | $8.65 | $1,228 |
| 80053 Clinical Chemistry | 43 | 19 | $10.35 | $445 |
| 83615 Clinical Chemistry | 38 | 18 | $5.92 | $225 |
| 82728 Clinical Chemistry | 27 | 16 | $13.36 | $361 |
| 83540 Clinical Chemistry | 27 | 16 | $6.34 | $171 |
| 84466 Clinical Chemistry | 26 | 16 | $12.50 | $325 |
| 82607 Clinical Chemistry | 21 | 15 | $14.78 | $310 |
Medicare prescription drug claims, 2024
In 2024, the drug Randy R Calegari prescribed most often to Medicare patients was Anastrozole, with 130 prescriptions and refills. In total Randy R Calegari wrote 1,425 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 130 | 306 | 31 | $1,090 |
| Prednisone Generic | 92 | 96 | 18 | $481 |
| Hydroxyurea Generic | 60 | 130 | 15 | $1,174 |
| Ondansetron Hcl Generic | 57 | 57 | 41 | $820 |
| Abiraterone Acetate Generic | 56 | 56 | Under 11 | $83K |
| Prochlorperazine Maleate Generic | 54 | 54 | 24 | $729 |
| Alendronate Sodium Generic | 52 | 130 | 14 | $356 |
| Megestrol Acetate Generic | 45 | 51 | 16 | $2,343 |
| Revlimid Lenalidomide | 43 | 43 | Under 11 | $782K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 40 | 40 | 13 | $946 |
| Potassium Chloride Generic | 37 | 44 | 16 | $702 |
| Eliquis Apixaban | 34 | 40 | Under 11 | $23K |
| Calquence Acalabrutinib Maleate | 33 | 33 | Under 11 | $499K |
| Gabapentin Generic | 31 | 36 | Under 11 | $244 |
| Ondansetron Odt Ondansetron | 31 | 31 | 14 | $418 |
Brand drugs: 320 claims; generic drugs: 1,105 claims; opioid claims: 113.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Randy R Calegari $14.76 ($14.76 in general payments such as food, travel and fees) from 1 company. The largest payer was Novartis Pharmaceuticals Corporation with $14.76.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 1 | $14.76 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.